Skip to main content
ADCT
NYSE Life Sciences

ADC Therapeutics' ZYNLONTA Phase 3 Trial Hits Primary Endpoint; sBLA Submission Planned for Q4 2026

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.9
Mkt Cap
$391.749M
52W Low
$2.55
52W High
$4.98
52W Position info
25% below low
Off High info
62% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

ADCT is trading near its 52-week low of $2.55 (25% below the low).

Summary

ADC Therapeutics announced positive Phase 3 LOTIS-5 trial results for ZYNLONTA, meeting the primary endpoint of progression-free survival (PFS) with a median PFS of 6.1 months versus 4.7 months for the control arm. This follows an 8-K filed earlier today disclosing the topline results. Positive Phase 3 results are a critical step towards expanding ZYNLONTA's label, which could significantly boost revenue for this ~$391M market cap biotech. While the safety profile showed higher serious adverse events, the efficacy data is strong. A pre-sBLA meeting with the FDA is planned for August, with a supplemental Biologics License Application (sBLA) submission targeted for Q4 2026.

At the time of this announcement, ADCT was trading at $1.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $391.7M. The 52-week trading range was $2.55 to $4.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

ADCT - Latest Insights

ADCT
Nov 04, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.72
Real-time Price: $1.72 info
Change: $0 (0%) info
Market Cap: $219.588M info
ADCT
Nov 03, 2026, 5:02 PM EST
Filing Type: S-4
Importance Score:
7
Price at Filing: $1.55
Real-time Price: $1.72 info
Change: +$0.170 (+11%) info
Market Cap: $219.588M info
ADCT
Oct 13, 2026, 6:26 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.82
Real-time Price: $1.72 info
Change: -$0.100 (-5%) info
Market Cap: $219.588M info
ADCT
Oct 08, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.33
Real-time Price: $1.72 info
Change: +$0.390 (+29%) info
Market Cap: $219.588M info
ADCT
Aug 13, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.06
Real-time Price: $1.72 info
Change: +$0.6608 (+62%) info
Market Cap: $219.588M info